Bonaparte Ilaria, Di Guglielmo Fiorella Cristina, Fragnoli Federica, Cuscito Rosilda, Indellicati Chiara, De Pascali Christian, Surgo Alessia, Carbonara Roberta, Davì Valerio, Gentile Maria Annunziata, Calbi Roberto, Caliandro Morena, Sanfrancesco Giuseppe, Aga Alberto, Cardetta Pietro, Antonicelli Michele, Ciocia Annarita, Curci Domenico, Ciliberti Maria Paola, Fiorentino Alba
Department of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti, 70021 Bari, Italy.
Department of Medicine and Surgery, LUM University, 70010 Casamassima, Italy.
J Pers Med. 2024 Nov 30;14(12):1134. doi: 10.3390/jpm14121134.
. Adult medulloblastoma (AMB) patients should receive postoperative craniospinal irradiation (CSI) as a standard treatment. Volumetric intensity-modulated arc therapy (VMAT) is a promising method for CSI. This report summarizes the repositioning and dosimetric data outcomes for six AMB patients. Complete CSI and posterior cranial fossa irradiation, or tumor bed boost irradiation with Linac-based VMAT, was performed and evaluated. Patients were immobilized in the supine position with two thermoplastic masks (head-neck and abdomen). To ensure inter-fraction reproducibility during radiotherapy (RT), a single cone-beam CT (CBCT) scan for each isocenter and real-time surface-guided RT using AlignRT were performed daily before and during the RT session. Match values of all three translational axes (x = lateral, y = longitudinal, z = vertical) were recorded. . From August 2022 to September 2023, six AMB patients were treated with CSI: three women and three men with a median age of 32 (22-42). All cases were classical MB, four were low risk, and two were defined as high risk due to the metastatic disease. All patients underwent surgery; two received a gross total resection. Low-risk patients received 36 Gy for CSI and a 54 Gy boost, while high-risk patients received 39 Gy for CSI. No significant toxicities greater than G2 were observed during RT, and only two cases reported decreased platelet counts. The dose to the organs at risk was low and acceptable. The mean dose to the heart, lungs, eyes, stomach, and thyroid were 4.4 Gy, 8.5 Gy, 12 Gy, 8.7 Gy, and 11 Gy, respectively. In terms of repositioning data, 124 CBCT scans were analyzed. Inter-fraction CBCT mean values for the study population in all translational directions were inferior to 2 mm in more than 90% of cases. . VMAT is a convenient and effective treatment for AMB. Positioning and immobilization with masks (head and neck plus abdomen) reduce inter-fraction motion.
成年髓母细胞瘤(AMB)患者应接受术后全脑全脊髓照射(CSI)作为标准治疗。容积调强弧形放疗(VMAT)是一种有前景的CSI治疗方法。本报告总结了6例AMB患者的重新定位和剂量学数据结果。采用基于直线加速器的VMAT进行了完整的CSI和后颅窝照射,或肿瘤床加量照射,并进行了评估。患者仰卧位,使用两个热塑性面罩(头颈和腹部)固定。为确保放疗(RT)期间分次间的可重复性,在RT疗程前和疗程中每天对每个等中心进行一次锥形束CT(CBCT)扫描,并使用AlignRT进行实时表面引导RT。记录所有三个平移轴(x = 横向,y = 纵向,z = 垂直)的匹配值。2022年8月至2023年9月,6例AMB患者接受了CSI治疗:3名女性和3名男性,中位年龄为32岁(22 - 42岁)。所有病例均为经典型髓母细胞瘤,4例为低风险,2例因转移性疾病被定义为高风险。所有患者均接受了手术;2例实现了全切除。低风险患者CSI剂量为36 Gy,加量剂量为54 Gy,而高风险患者CSI剂量为39 Gy。RT期间未观察到大于2级的明显毒性反应,仅2例报告血小板计数下降。危及器官的剂量较低且可接受。心脏、肺、眼睛、胃和甲状腺的平均剂量分别为4.4 Gy、8.5 Gy、12 Gy、8.7 Gy和11 Gy。在重新定位数据方面,分析了124次CBCT扫描。研究人群在所有平移方向上的分次间CBCT平均值在90%以上的病例中低于2 mm。VMAT是一种方便有效的AMB治疗方法。使用面罩(头颈加腹部)进行定位和固定可减少分次间运动。